| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 31st May 2025 |
| for |
| Sycamore Life Sciences Limited |
| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 31st May 2025 |
| for |
| Sycamore Life Sciences Limited |
| Sycamore Life Sciences Limited (Registered number: 09053630) |
| Contents of the Financial Statements |
| for the Year Ended 31st May 2025 |
| Page |
| Balance Sheet | 1 |
| Notes to the Financial Statements | 2 |
| Sycamore Life Sciences Limited (Registered number: 09053630) |
| Balance Sheet |
| 31st May 2025 |
| 31.5.25 | 31.5.24 |
| Notes | £ | £ |
| CURRENT ASSETS |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 5 |
| NET CURRENT LIABILITIES | ( |
) | ( |
) |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
) |
( |
) |
| CAPITAL AND RESERVES |
| Called up share capital | 6 |
| Retained earnings | ( |
) | ( |
) |
| SHAREHOLDERS' FUNDS | ( |
) | ( |
) |
| The directors acknowledge their responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| Sycamore Life Sciences Limited (Registered number: 09053630) |
| Notes to the Financial Statements |
| for the Year Ended 31st May 2025 |
| 1. | COMPANY INFORMATION |
| Sycamore Life Sciences Limited is a |
| Registered number: |
| Registered office: |
| The presentation currency of the financial statements is the Pound Sterling (£). |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Tangible fixed assets |
| Tangible Fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment loss. |
| Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis: |
| Fixtures and Fittings - 25% on cost |
| The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the profit or loss. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Sycamore Life Sciences Limited (Registered number: 09053630) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31st May 2025 |
| 2. | ACCOUNTING POLICIES - continued |
| Going concern |
| Due to the the impact of the covid19 pandemic the company reports negative reserves at the balance sheet date. However, the directors are of the opinion that this is likely to change in the next financial year and they will continue to support the company as they have done throughout the current year. At the time of approving the financial statements, the directors have a reasonable expectation that the company will have adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| 4. | TANGIBLE FIXED ASSETS |
| Fixtures |
| and |
| fittings |
| £ |
| COST |
| At 1st June 2024 |
| and 31st May 2025 |
| DEPRECIATION |
| At 1st June 2024 |
| and 31st May 2025 |
| NET BOOK VALUE |
| At 31st May 2025 |
| At 31st May 2024 |
| 5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 31.5.25 | 31.5.24 |
| £ | £ |
| Directors' current accounts | 10,097 | 4,187 |
| Accrued expenses |
| 6. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 31.5.25 | 31.5.24 |
| value: | £ | £ |
| Ordinary A | £1 | 1,000 | 1,000 |
| Sycamore Life Sciences Limited (Registered number: 09053630) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31st May 2025 |
| 7. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES |
| The following advances and credits to directors subsisted during the years ended 31st May 2025 and 31st May 2024: |
| 31.5.25 | 31.5.24 |
| £ | £ |
| Balance outstanding at start of year | ( |
) | ( |
) |
| Amounts advanced |
| Amounts repaid | ( |
) | ( |
) |
| Amounts written off | - | - |
| Amounts waived | - | - |
| Balance outstanding at end of year | ( |
) | ( |
) |
| The loan is repayable on demand and no interest was charged during the year. |
| 8. | ULTIMATE CONTROLLING PARTY |
| The company is under the joint control of the directors by virtue of their joint holding of 100% of the voting share capital. |